Search

Your search keyword '"Kong, George"' showing total 150 results

Search Constraints

Start Over You searched for: Author "Kong, George" Remove constraint Author: "Kong, George"
150 results on '"Kong, George"'

Search Results

2. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

3. Two-year outcomes of Xen 45 gel stent implantation in patients with open-angle glaucoma: real-world data from the Fight Glaucoma Blindness registry.

4. Performance of a Deep Learning System and Performance of Optometrists for the Detection of Glaucomatous Optic Neuropathy Using Colour Retinal Photographs.

6. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial

12. LP-184 Rationale and design of two phase 3, Randomized, double-blind, placebo-controlled studies of the efficacy and safety of litifilimab in adults with active systemic lupus erythematosus: TOPAZ-1 and TOPAZ-2

14. Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection

15. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial

23. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

24. Primary Results of NOVA: a Randomized Controlled Study of the Efficacy of 6 - Week Dosing of Natalizumab Versus Continued 4-Week Treatment for Multiple Sclerosis (S14.005)

28. Résultats primaires de NOVA : une étude contrôlée randomisée comparant l’administration de natalizumab toutes les 6 semaines versus une administration continue toutes les 4 semaines dans le traitement de la sclérose en plaques

41. Should this artificial intelligence algorithm be used in my practice now? A checklist approach: Response.

43. An open-label, phase 2 study of nivolumab in combination with either rucaparib, docetaxel, or enzalutamide in men with castration-resistant metastatic prostate cancer (mCRPC; CheckMate 9KD).

45. Glaucoma.

48. Anti-PEG antibody bioanalysis: a clinical case study with PEG-IFN-λ-1a and PEG-IFN-α2a in naive patients

Catalog

Books, media, physical & digital resources